Member Info for Nolupus

Don't worry Wigwammer ha e some fun ...

My way of thinking has not seen me too wrong so car ..

But just two words have got me thinking ' outside the box '

- preclinical

- personalized médicine

Let you figure it out for yourself and everyone to their own as per usual ...

Pump and dump crowd here today ??

One should always think outside the box , imo

Change of auditors ,with immediate effect , so that the new auditors will take on this year's audit ....Humm

IS this strange or IS this strange ?

What do you think Dallo ?

Many OVER estimate the complexity , imo

There are realy only two things that take time and effort

1) Regulatory approval ( which after years of talks with the FDA should have been ironed out a very long Time ago )

2) Financial considerations

Whilst we have been told that Avion are footing the bill ( up to $25 million , we have yet to see any real investment actually spent by them ..

If ' market sentiment' is So bad , it could be because the companys track record is terrible ( all talk and much promises but delivering very little )

But whatever , everyone to their own views as per usual

Formelyeasyp,

I cannot answer your questions as

I don't know ..

P.s. Everyone to their own trades and strategy but keep an eye on the US clinical trial website....

Best regards

Oldbutnowisa,

I should have said that they don't do Independent research for IMM..just organizing the 'future P3 trial " .. ( which IS still not published on the clinical trial website ) ...

Oldbutnowisa,

Simbec Orion are a CRO , they don't do Independent research , they just organize the clinical trials ...

Best regards

Idon't think this appointement makes any difference, tbh

If one IS being objective, this is probably a part Time position and the title of CFO is imo , very glorified , bwtfdik ...

Cauldstream7,

I will remind you of one thing...

After the last P3 trial results came out , Prof Muller issued a CNRS press release which claimed that the trial was a success. This press release caused uproar and many scientists and lupus experts called on the CNRS to withdraw that release ( which they did ) .

Prof Muller IS a very distinguished professeur, don't get me wrong but at her age , I don't know if she IS still actively engaged in research or just giving some lectures .

Let's Hope it all Comes to something for all those lupus patients ...

Best regards

Ultrainvestor,

Sorry to hear about your losses, especially as you were a ' strong buy' poster here for quite some Time ...

What made you sell up ?

: RE: RNS out31 Aug 2022 09:35

Time to load up people, i've just bought 100k!! Will sell at 12p on FDA Approval

imho, dyor, nai

Wigwammer,

I think the regulatory issues were already ironed out after all those FDA meetings and guidances...

Wigwammer,

Whilst I may agree that partnership timeli es are uncertain, i disagree about clinical trial setup timeframes .

The CRO was appointed nearly a year ago

This is , in my humble opinion, a very rare situation. ( The P3 trial IS not even registered on the clinical trial website)

Dallo,

I wouldn't say worthless, as i think the patent infringement allegations will come to nothing .

It will probably take time but they should eventually make some money for Imm to compensate the loss they took in selling their shares this year ....

I am more worried about the lack of any news on the ' future P3 trial ' tbh.

Let's see what happens next ...

Wigwammer,

Do you think that IMM Can afford to buy back shares in Incanthera at the moment ?

Hopefuly the patent infringement allegations will be resolved asap .

Couldn't come at a worse time for Incanthera shareholders at any rate

Newsflow is necessary to keep spirits up now, as there is only doom and gloom here presently...

The Incanthera SP has tanked and we still don't know when the P3 trial will be starting ( if ever ) .

Frustrating times for all and patience IS dwindling , imo

Cauldstream7,

For your information, no patients Can be recruited Until the study protocol has bien published on the clinical trial website .

Tim seems to be juggling with his two hands , Inc and Imm whilst shareholders in both companies are struggling with their paper losses ...

Markets are markets ..

Dallo,

Why do you think it's correct for investir relations to Reply only to registrted shareholders ?

As they well know most shareholders are not registered so in my Book , that IS unfair treatment for the majority ...

Whatever...

Dallo,

In for a penny, in for a pound , comes to mind...

You will soon have to do a takeover bid 😂

Dallo,

As you know, only two things matter in biotechs

1) Cash

2) advancing the science

If one is objective, Imm seems to be lacki g on both fronts , but Tim needs to pull some rabbits from his hat and very quickly, imo